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Objective: Percutaneous aortic valve implantation has been performed clinically in
high-risk patients with severe aortic stenosis. Transfemoral retrograde valve delivery
is limited by concomitant peripheral vascular disease and the size of the delivery sys-
tem. We report on the alternative transapical approach that allows accurate antegrade
placement of a catheter-deliverable aortic valve.
Methods: Over a 2-year period, 26 consecutive patients (84.3 6 6.5 years) were
treated at our center. Transapical aortic valve implantation was performed with 23-
mm and 26-mm pericardial valves (Cribier–Edwards; Edwards Lifesciences, Irvine,
Calif) mounted on a stainless steel stent. A limited anterolateral incision, in the fifth
intercostal space, was used to access the apex of the heart. The valve was crimped,
placed into a 24F sheath, and introduced into the left ventricle through purse-string
sutures. Fluoroscopy and transesophageal echocardiography were used to guide the
catheter across the native valve and to direct deployment of the stent at the level of
the annulus. During deployment, the heart was unloaded with extracorporeal support
or with rapid ventricular pacing. The average logistic EuroSCORE-predicted risk for
mortality was 36.5% 6 5.8%.
Results: All valves were successfully deployed at the target. On echocardiography, all
valves showed good hemodynamic function with only minor paravalvular leakages.
The mean transaortic valve gradient was 6 6 2 mm Hg. Thirty-day mortality was
15% (n5 4). One patient died of perforation of the right ventricle and 1 of dissection
of the aortic root. There were 2 cases of conversion to open surgery. In 2 patients, the
left main stem was partially obstructed by the native valve and required stent angio-
plasty.
Conclusions: Initial results of the transapical approach are encouraging. Long-term
studies and randomized protocols will be required to further evaluate this
procedure.
A
ortic valve replacement (AVR) with cardiopulmonary bypass (CPB) is the es-
tablished gold standard in the treatment of symptomatic severe degenerative
aortic stenosis that offers both symptomatic relief and the potential for im-
proved long-term survival.1 However, because many of the typically elderly patients
with symptomatic severe aortic stenosis have significant comorbidities, open AVR
with CPB can be associated with an unacceptable perioperative mortality and morbid-
ity. Thus, there is an ongoing attempt to evaluate and to define alternative treatment
options for these highest risk patients. Managed medically, symptomatic patients
have a poor prognosis and the hope of long-term benefit with balloon aortic valvulo-
plasty has not been realized owing to a high necessity of reinterventions.2-5 Still, this
technique served as a precursor for the rapidly evolving field of transcatheter-based
aortic valve implantation (AVI), which selected centers have recently started to pur-
sue.6-10 Percutaneous AVI in humans was first performed as a femoral transvenous
procedure with antegrade access to the aortic valve by Cribier and colleagues.6-8 Sub-
sequently, a technically less challenging retrograde femoral transarterial procedure
has been reported that can be problematic owing to concomitant peripheral vascular
disease as well as the size of the delivery system.11,12 Animal developmental work
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AVI 5 aortic valve implantation
TAP–AVI 5 transapical aortic valve implantation
AVR 5 aortic valve replacement
CPB 5 cardiopulmonary bypass
with direct balloon catheter implantation of an aortic valve
through the left ventricular apex further broadened the spec-
tra of transcatheter based AVI.9,10 Recently, the first success-
ful clinical case in which this approach was used to implant
an aortic valve without CPB was published.13 The purpose
of the current investigation was to report our initial clinical
experience in 26 consecutive patients who underwent ante-
grade placement of a catheter-deliverable aortic valve (Crib-
ier–Edwards; Edwards Lifesciences, Irvine, Calif) through
the left ventricular apex at our institution.
Patients and Methods
Patient Selection: Inclusion criteria
High-risk patients with severe symptomatic aortic stenosis and an
aortic valve orifice area of 0.8 cm2 or less were selected for the pur-
pose of this study. High risk was defined by a logistic EuroSCORE
predicted risk for mortality greater than 20%.14 Additional inclusion
criteria were an age of 75 years or older, echocardiographically mea-
sured aortic annulus diameter of 24 mm or less, as well as symmet-
rically distributed calcification of the stenotic native aortic valve
cusps. The novel therapeutic option of transapical aortic valve im-
plantation (TAP–AVI) was discussed extensively with all patients
considered suitable for inclusion in the study, focusing on the over-
all risk profile of the individual patient, on the preoperative activities
of daily living, the motivation of the individual patient, and on the
ongoing results of the new technique. Applying these guidelines,
we treated 26 consecutive patients (84.36 6.5 years) between Feb-
ruary 2006 and February 2008 at the Hospital of the Johann Wolf-
gang Goethe University, Frankfurt/Main, Germany, with an
average logistic EuroSCORE predicted risk for mortality of 36.5%
6 5.8%. The study was approved by the institutional review board
and informed consent and permission for the release of information
were obtained from each patient. Patient demographics are summa-
rized in Table 1.
Patient Selection: Exclusion criteria
The presence of one or more of the following comorbidities was
considered a contraindication for TAP–AVI : echocardiographically
measured aortic annulus diameter of more than 25 mm, noncalcified
aortic stenosis, subvalvular aortic stenosis, bicuspid aortic valve, in-
tracardiac thrombus or vegetation, endocarditis, untreated symp-
tomatic coronary artery disease, myocardial infarction within less
than 1 month, ejection fraction less than 20%, recent stroke, and
hypertrophic obstructive cardiomyopathy.
Procedure
All operations were performed in a specially equipped angiography
suite that fulfills the standards of a hybrid operating room. A mono-The Journal of Thorplane fluoroscopic angiography system (Axiom Sensis; Siemens,
Munich, Germany) was used. Fluoroscopy is important for allowing
an optimal delineation of the level of the aortic annulus in relation to
the aortic sinuses, along with imaging of the coronary ostia. Besides
standard hemodynamic monitoring, transesophageal echocardiogra-
phy and CPB were routinely available. Transesophageal echocardi-
ography was used for repeated measurements of aortic annular
diameters. Using an oversizing technique, we chose a valve size
that was 2 to 3 mm larger than the echocardiographic annular mea-
surements to achieve good contact with the aortic annulus and to
minimize the risk of paravalvular leaks.
The valve was prepared for transapical antegrade delivery under
sterile conditions in the operating room. The delivery catheter was
flushed with a heparinized saline solution. The deployment balloon
was primed with a mixture of saline and contrast that was free of air.
The valve was crimped onto the deployment balloon so that it was
equidistant between two radiopaque markers and was able to be
passed through the 33F transapical delivery sheath. All valve de-
ployments were performed with standard volumetric inflation of
the balloon. Fluoroscopy and transesophageal echo were used to
guide the catheter across the native valve and direct deployment
of the stent at the level of the annulus. During deployment, the heart
was unloaded with CPB or with rapid ventricular pacing. The Crib-
ier–Edwards prosthesis is a pericardial xenograft mounted on a stain-
less steel stent and is available in two sizes: 23 mm and 26 mm
(Figure 1).7-9,14
Patients were placed in a supine position. The femoral vessels
were exposed, either for cannulation for CPB or to place a venous
TABLE 1. Demographic characteristics of study population
No. of patients 26
Age (y) 84 6 7
Gender (male) 6 (23%)
Ejection fraction , 30% 5 (19%)
History of tobacco use 18 (69%)
Respiratory dysfunction/COPD 8 (31%)
Diabetes mellitus 8 (31%)
Renal failure 10 (38%)
Renal failure on dialysis 2 (8%)
Coronary artery disease* 11 (42%)
Presence of mitral incompetence# II y 5 (19%)
Recent cardiac decompensation 8 (31%)
Peripheral vascular disease 4 (15%)
Porcelain aorta 3 (12%)
NYHA class 3.560.4
Previous cardiac surgery 3 (12%)
Aortic valve orifice area (cm2) 0.6 6 0.1
Previous stroke 3 (12%)
Pulmonary hypertension 7 (27%)
Arrhythmia 8 (31%)
EuroSCORE predicted risk for mortalityz 36.5% 6 5.8%
COPD, Chronic obstructive pulmonary disease; NYHA, New York Heart As-
sociation; n (%) is listed for categorical variables; mean6 1 standard devi-
ation for normally distributed continuous variables. *Diffuse coronary artery
disease without any indication for surgical treatment or status-post percu-
taneous transluminal coronary angioplasty; yno indication for concomitant
surgical valve repair; zaccording to logistic EuroSCORE calculations.acic and Cardiovascular Surgery c Volume 136, Number 4 949
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order to be prepared for fast cannulation. In addition, a femoral ar-
terial sheath (6F) was inserted and an aortic root pigtail catheter for
angiographic visualization was placed. High-dose heparin (300 IU/
kg) was given for on-pump cases, and low-dose heparin (5000 IU)
was used for off-pump procedures, with a target activated clotting
time of 180 to 200 seconds. A limited anterolateral incision (5–7
cm), in the fifth intercostal space, was used to access the apex of
the heart. A bipolar epicardial pacing wire was placed and tested.
Two U stitches with Teflon felt pledgets using 3-0 Prolene polypro-
pylene (Ethicon, Inc, Somerville, NJ) were placed in the apex of the
left ventricle. They served as a purse string for linear closure of the
left ventricle at the end of the procedure. The left ventricular apex
was punctured and a soft guidewire passed in an antegrade fashion
across the stenotic aortic valve under fluoroscopic and echocardio-
graphic guidance. A 14F soft sheath was introduced and positioned
across the aortic valve. A 03500 super-stiff guidewire (Amplatz Su-
per Stiff; 260 cm, Boston Scientific, Natick, Mass) was then posi-
tioned across the aortic arch and placed into the descending aorta.
The sheath was partially withdrawn and a 20-mm balloon valvulo-
plasty catheter positioned under fluoroscopic and echocardiographic
guidance. Balloon valvuloplasty was performed once during a brief
episode of rapid ventricular pacing (150 beats/min). The balloon
catheter and apical sheath were withdrawn and a 33F transapical de-
livery sheath inserted bluntly. The valve was then inserted with the
specific application system. After careful de-airing of the sheath, the
valve was positioned so that the annulus bisects the stent. Fluoro-
scopic and echocardiographic imaging was used to position the
valve, and single shot aortic root angiography was used to confirm
the intra-annular position below the coronary ostia. During a second
brief episode of rapid ventricular pacing, the valve was almost
Figure 1. Edwards SAPIEN THV, a xenograft consisting of 3 bovine
pericardial cusps with Thermafix treatment mounted in a balloon-
expandable stainless steel stent.950 The Journal of Thoracic and Cardiovascular Surgery c Octinstantaneously implanted with rapid balloon inflation. Rapid pac-
ing was then stopped to allow for hemodynamic recovery. Repeat
dilatation was indicated in the presence of moderate paravalvular
leakage. Valve function was immediately assessed by angiographic
and echocardiographic visualization. The transapical sheath was re-
moved and the apex securely closed with the purse-string sutures.
CPB was weaned, if necessary, the cannulas removed, and prot-
amine administered. Intercostal blockade was performed with ropi-
vacaine. The pericardium was partially closed over the apex and
a left lateral chest tube inserted. The incision was closed in a standard
fashion. Perioperative images of TAP–AVI are displayed in Fig-
ure 2. Postoperative device-specific medical therapy consisted
only of aspirin 100 mg daily.
Statistical Evaluation
For the purpose of this report, no specific statistical evaluations were
deemed necessary. Continuous data are reported as mean 6 1
standard deviation or median with intraquartile range if appropriate.
Categorical variables are expressed as percentages.
Results
Perioperative Results
In 15 patients (58%) TAP–AVI was performed after cannula-
tion of the femoral vessels. With increasing experience, how-
ever, femoral cannulation only was performed without CPB
(n 5 4, 15%). Recently, the majority of patients received
off-pump valve implantation with only a femoral venous
and arterial wire in place. For an intraoperatively measured
aortic annulus diameter of 21.8 6 1.8 mm, we implanted
a 256 1.6-mm aortic valve representing an oversizing of ap-
proximately 15%. All valves were successfully deployed at
the target. In 1 patient, valve embolization into the aortic
arch occurred during a second inflation of the balloon owing
to a severe paravalvular leakage. On control echocardiogra-
phy, all other valves showed good hemodynamic function.
Repeat valve dilatation was performed because of uneven
stent expansion leading to moderate or severe paravalvular
leak in 6 (23%) patients. Four (15%) patients retained mild
to moderate (I–II) aortic insufficiency owing to paravalvular
leakages. There was no case of substantial intraprosthetic
central aortic insufficiency. The mean transaortic valve gradi-
ent was 6 6 2 mm Hg. There were 2 cases of conversion to
open surgery including the patient with valve embolization
and another patient with a porcelain aorta in whom a type
A dissection developed after balloon dilatation. In 2 patients,
the left main stem was partially obstructed by the native valve
and required stent angioplasty, which was performed
successfully. Three patients had severe hypotension after
off-pump deployment of the valve requiring transitory CPB
support. Two of them fully recovered within 10 and 15 min-
utes and could be weaned from CPB without difficulties. The
third patient was transferred to the intensive care unit with an
intra-aortic balloon pump that stayed in place for 2 days and
could then be explanted. There was 1 intraoperative death re-
sulting from aortic root dissection during valve deployment.ober 2008
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CDFigure 2. Perioperative imaging demonstrating
20-mm balloon dilatation of the stenotic aortic
valve (A), antegrade delivery, correct positioning
(B), and deployment (C) of the prosthesis. A perio-
perative angiogram demonstrated excellent posi-
tion and function of the bioprosthesis. There is no
evidence of intraprosthetic or periprosthetic in-
sufficiency (D). The left and right coronary
ostia are patent (E).Overall, procedure times accounted for 152 6 87 minutes.
Procedural characteristics are summarized in Table 2.
Hospital Course
Two patients (8%) underwent re-exploration for bleeding
(Table 3). One patient had a wound infection in the groin after
femoral cannulation. No patient from this series had a stroke.
Thirty-day mortality was 15% (n 5 4) including the 1 intra-
operative death resulting from dissection of the aortic root
and 1 death 6 hours after surgery caused by perforation of
the right ventricle. Perforation of the right ventricle occurred
while the guidewire for venous cannulation was being
advanced through the groin. There were another 2 non–
valve-related deaths in patients with multisystem organ fail-
ure on postoperative days 3 and 5. The postoperative course
in these 2 patients was complicated by leg ischemia after can-
nulation of the femoral vessels in 1 patient and development
of a Leriche syndrome in the second patient. Postmortem as-
sessment in both patients confirmed good prosthetic valve
position and function, as well as patent coronary ostia.
Discussion
Reflecting an aging society, patients requiring cardiac sur-
gery are steadily getting older and have more comorbidities.The Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 4 951
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affecting the elderly patient population. To counteract this
development, conventional surgical AVR continuously
improved over the years with regard to the hemodynamic
performance of the implanted valves, additional organ pro-
tection measures, and postoperative care adjusted to the spe-
cific needs of these patients. Thus, classic surgical AVR still
improves symptoms and prognoses in most cases.15,16 How-
ever, despite all efforts, mortalities may be as high as 20% in
patients with left ventricular dysfunction,17 and some have
even been considered nonsurgical candidates.
Percutaneous implantation of a stent type aortic valve
became a clinical reality with the first reported successful hu-
man case by Cribier and colleagues6 in 2002. Subsequently,
intense interest has formed toward the development of a cath-
eter-delivered valve for use in patients with critical aortic ste-
nosis declined for surgery. The percutaneous retrograde
approach can be problematic because of the obligatory size
of the 24F delivery sheath.18 Many of these elderly patients
have coexisting peripheral vascular disease that precludes
passing large sheaths or catheters from the groin, around
the arch of the thoracic aorta, and across the aortic valve an-
nulus. Moreover, this technique also runs the risk of embol-
izing atherosclerotic material from the aorta into the distal
circulation, including cerebral arteries, causing severe neuro-
logic complications including stroke.12 We therefore believe
that the transapical approach provides a reliable and attractive
alternative. The distance of the aortic valve from the left ven-
tricular apex is straight and relatively short, which provides
good control over the delivery catheter. This optimal control
over the placement of the valve was confirmed in previous
TABLE 2. Operative results
Aortic annulus diameter (mm) 21.8 6 1.8
Implanted valve size (mm) 25.0 6 1.6
23-mm prosthesis (n) 11 (42%)
26-mm prosthesis (n) 15 (58%)
Good valve positioning (n) 25 (96%)
Conversion to sternotomy (n) 2 (8%)
Type A dissection (n) 1 (4%)
Valve migration after repeat valve dilation (n) 1 (4%)
Use of CPB (n) 11 (42%)
Cannulation for CPB (n) 15 (58%)
Implantation off-pump (n) 15 (58%)
Repeat valve dilation (n) 6 (23%)
Severe hypotension (n) 3 (12%)
Intra-aortic balloon pump (n) 2 (8%)
Obstruction of coronaries (n) 2 (8%)
Concomitant stent PTCA (n) 2 (8%)
Operative time (minutes) 152 6 87
Intraoperative death (n) 1 (4%)
CPB, Cardiopulmonary bypass; PTCA, percutaneous transluminal coronary
angioplasty; n (%) is listed for categorical variables; mean 6 1 standard
deviation for normally distributed continuous variables.952 The Journal of Thoracic and Cardiovascular Surgery c Ocanimal series in which all valves were deployed at the
intended target site.9,10 Additionally, TAP–AVI carries the
potential advantage of avoiding the aortic arch, which in
patients with calcified aortic stenosis is frequently subject
to atherosclerotic changes.
In the presence of numerous simultaneously evolving
strategies for transcatheter-based AVI, a reliable preoperative
risk assessment will be critical to compare clinical results of
different approaches in the future. Application of the numeric
and logistic EuroSCORE allows the preoperative estimate of
perioperative risk19,20 and has also been used for the purpose
of this investigation. We are aware of the observation that
specifically the logistic EuroSCORE may overestimate the
actual risk to the individual patient.21 However, in the ab-
sence of a uniformly accepted and validated risk stratification
model, we had to use the EuroSCORE estimate to comply
with data presented in recent clinical series.7,12,14
The current clinical report confirms that TAP–AVI is fea-
sible, leading to an immediate decrease in the transaortic
mean gradient. The total procedure time decreased with
increasing experience throughout the study. Currently,
a straightforward transapical valve implantation can be rou-
tinely performed in less than 80 minutes. Initially, it was
our belief that circulatory support with CPB may represent
a safer alternative to brief rapid cardiac pacing in patients
with severe aortic stenosis and left ventricular hypertrophy
inasmuch as low cardiac output may lead to myocardial
ischemia and subsequent hemodynamic instability. With
gained clinical experience, we felt more comfortable to
identify patients who may be at higher risk for hemodynamic
deterioration before deployment of the valve. Typically,
patients who had stable perioperative hemodynamics
and responded well to low doses of norepinephrine by an
acute increase in systolic arterial pressure tolerated rapid
pacing without difficulties. Furthermore, it was helpful to
TABLE 3. Postoperative outcome
Length of mechanical ventilation, median (h) 6.4 (IQR: 4.1–8.3)
ICU stay, median, (h) 18.0 (IQR: 12.8–23.4)
Postoperative complications
Re-exploration (n) 2 (8%)
Stroke (n) 0
Supraventricular arrhythmia (n) 5 (19%)
Transient hemofiltration (n) 3 (12%)
30-day mortality (n) 4 (15%)
Aortic annulus rupture (intraoperative) (n) 1 (4%)






Multiorgan failure/leg ischemia (POD 5) (n) 1 (4%)
POD, Postoperative day; categorical variables are listed as median with in-
traquartile range (IQR) for nonnormally distributed continuous variables
where appropriate.tober 2008
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temic arterial pressure before rapid ventricular pacing during
valve deployment with low doses of norepinephrine. In our
experience, a targeted systolic peripheral arterial pressure
of 120 to 140 mm Hg seemed to be ideal.
In summary, initial results of the transapical approach for
AVI in a cohort of older and high-risk surgical patients at our
institution can be considered encouraging. Notably, perma-
nent neurovascular complications were absent as compared
with the reported experience with endovascular transcath-
eter-based AVI. Future routine clinical application of this
emerging approach will be dependent on further technical
improvements and gained operative experience, leading to
a decreased mortality and morbidity with short- and long-
term results comparable with conventional AVR surgery,
which remains the gold standard.
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